The decision, issued without the input of an official advisory committee, revises long-held labeling on the drugs cautioning ...

Analysts suspected that the mid-stage trial miss wouldn't ding Neurocrine’s share price since expectations around the program were "near-zero." ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...

Merck’s pill, which could be the first oral PCSK9 drug to get to market, displayed similar effects on lipid levels as ...

Soleno shares fell double digits amid questions about the growth trajectory of its Prader-Willi drug. Elsewhere, a cancer ...

Without taking a firm position, the antitrust agency said Novo’s two-step deal structure may illegally sidestep requirements for a premerger review.

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight loss-focused startup it helped launch last year.

The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...

The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted developer of obesity drugs.